^
HR positive
HER2 Negative Breast Cancer
exemestane
Sensitive: A2 - Guideline
SABCS 2021 - 1 week
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
SABCS 2021 - 1 week
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
JAMA Oncol - 1 week
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
FDA - 1 week
HR positive
HER2 Negative Breast Cancer
ribociclib + letrozole
Sensitive: B - Late Trials
SABCS 2021 - 1 week
HR positive
HER2 Negative Breast Cancer
EC
Sensitive: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
PIK3CA H1047R + PIK3CA D959N + ER E380Q
HER2 Negative Breast Cancer
abemaciclib
Resistant: C4 – Case Studies
Front Endocrinol (Lausanne) - 1 week
HR negative
HER2 Negative Breast Cancer
AMG479
Sensitive: C3 – Early Trials
Nature - 2 weeks
HR positive
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: C2 – Inclusion Criteria
SAGE Journals - 3 weeks
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HER-2 negative
HER2 Negative Breast Cancer
CaT
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
ER positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
docetaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
bevacizumab
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
ixabepilone
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
toremifene
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
ER positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
everolimus
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
TC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + anastrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
fulvestrant + letrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
palbociclib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
exemestane
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
ER positive + PGR positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
EC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
CMF
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
paclitaxel
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
AC
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
TAC
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
GT
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
epirubicin
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
cyclophosphamide oral
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
lyso-thermosensitive liposomal doxorubicin
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
doxorubicin hydrochloride
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
estradiol
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
megestrol
Sensitive: A2 - Guideline
HR negative + PD-L1 expression
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
HR negative + PD-L1 expression
HER2 Negative Breast Cancer
atezolizumab
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
PGR positive
HER2 Negative Breast Cancer
anastrozole
Sensitive: A2 - Guideline
PGR positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor + alpelisib
Sensitive: A2 - Guideline
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor + alpelisib
Sensitive: A2 - Guideline
BRCA2 mutation + HR positive
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
BRCA1 mutation + HR positive
HER2 Negative Breast Cancer
olaparib
Sensitive: A2 - Guideline
HER-2 negative
HER2 Negative Breast Cancer
POL 6326
Sensitive: B - Late Trials
PIK3CA mutation + ER positive
HER2 Negative Breast Cancer
GDC-0032
Sensitive: B - Late Trials
PIK3CA mutation
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
gimeracil/oteracil/tegafur
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
PI3K inhibitor
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
DJ 927
Sensitive: B - Late Trials
BRCA2 mutation
HER2 Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
BRCA1 mutation
HER2 Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
SNDX-275
Resistant: B - Late Trials
HR positive
HER2 Negative Breast Cancer
capecitabine + DJ 927
Sensitive: B - Late Trials
ER positive + PGR negative + HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
chidamide
Sensitive: B - Late Trials
PIK3CA E542K + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
PIK3CA H1047X
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
PIK3CA E545X
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
GDC-0032
Sensitive: B - Late Trials
TP53 mutation
HER2 Negative Breast Cancer
talazoparib
Resistant: B - Late Trials
HR positive
HER2 Negative Breast Cancer
SHR6390
Sensitive: B - Late Trials
ER mutation
HER2 Negative Breast Cancer
Aromatase inhibitor + palbociclib
Resistant: B - Late Trials
HIF1A overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: B - Late Trials
BACH1 overexpression
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
oral paclitaxel/encequidar
Sensitive: B - Late Trials
BRCA1 mutation+ HER-2 negative
HER2 Negative Breast Cancer
olaparib
Sensitive: B - Late Trials
BRCA2 mutation + HER-2 negative
HER2 Negative Breast Cancer
olaparib
Sensitive: B - Late Trials
ER positive
HER2 Negative Breast Cancer
EC-P
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
CT7001
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
docetaxel
Sensitive: B - Late Trials